Current advances in HIV vaccines.
Development of a safe and preventive HIV-1 vaccine is a high priority. Recent advances in HIV vaccine development include an improved understanding of HIV envelope structure, development of techniques that enable a detailed analysis of vaccine-induced immune responses in humans, expansion of the pipeline of promising candidate vaccines, and completion of the first vaccine efficacy trials. A common feature of several preventive vaccine strategies in early clinical trials is their ability to attenuate clinical disease rather than completely prevent HIV infection in nonhuman primates. One or more candidate vaccines will likely advance into efficacy trials within the next few years, while efforts to identify new designs that induce broadly neutralizing antibodies continue with incremental success.
D'Souza
M Patricia
MP
Division of AIDS, National Institute of Allergy and Infectious Diseases, National Institutes of Health, 6700B Rockledge Drive, Room 5127, Bethesda, MD 20892, USA. pdsouza@niaid.nih.gov
Allen
Mary
M
Sheets
Rebecca
R
Johnston
Margaret I
MI
D016915:AIDS Vaccines; D015658:HIV Infections / Q000517:prevention & control*; D015497:HIV-1 / Q000276:immunology*; D006801:Humans
D016915:AIDS Vaccines